The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.
Cancer Policy

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

By Sara Willa Ernst
Drugs & Targets

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.
Clinical Roundup

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account